Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of Net Margin data on record, last reported at 13.21% in Q4 2025.

  • For Q4 2025, Net Margin rose 2869.0% year-over-year to 13.21%; the TTM value through Dec 2025 reached 4.3%, up 7976.0%, while the annual FY2025 figure was 4.3%, 7976.0% up from the prior year.
  • Net Margin reached 13.21% in Q4 2025 per ARQT's latest filing, up from 7.47% in the prior quarter.
  • Across five years, Net Margin topped out at 13.21% in Q4 2025 and bottomed at 15123.72% in Q3 2022.
  • Average Net Margin over 4 years is 1646.0%, with a median of 156.74% recorded in 2023.
  • Peak YoY movement for Net Margin: skyrocketed 1497429bps in 2023, then soared 2869bps in 2025.
  • A 4-year view of Net Margin shows it stood at 2432.25% in 2022, then soared by 80bps to 490.05% in 2023, then surged by 97bps to 15.49% in 2024, then soared by 185bps to 13.21% in 2025.
  • Per Business Quant database, its latest 3 readings for Net Margin were 13.21% in Q4 2025, 7.47% in Q3 2025, and 19.49% in Q2 2025.